Last reviewed · How we verify

NCT06891521

Electroacupuncture for Preventing Adverse Events of Cancer Immunotherapy

Not yet recruiting Phase 2 Last updated 24 March 2025
What this trial tests

Phase 2 trial testing Electroacupuncture in Cancer in 123 participants. Not yet recruiting.

Timeline
20 March 2025
Primary endpoint
1 March 2027
1 June 2028

Quick facts

Lead sponsorQinghai Red Cross Hospital
PhasePhase 2
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeprevention
Enrollment123
Start date20 March 2025
Primary completion1 March 2027
Estimated completion1 June 2028
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Qinghai Red Cross Hospital

Who can join

Adults 18 to 80, any sex, with Cancer or Adverse Events. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate the preventive effects of electroacupuncture on immune-related adverse events (irAEs) in patients with malignant solid tumors at the neoadjuvant stage, locally advanced, unresectable, or metastatic stages, who are receiving immune checkpoint inhibitors (ICIs) monotherapy, ICIs combined with anti-angiogenic agents, or ICIs combined with chemotherapy. The study will evaluate the efficacy, safety and mechanisms of electroacupuncture in preventing irAEs in a multicenter setting.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Electroacupuncture

Trials testing the same drug.

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other Qinghai Red Cross Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06891521.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing